Business briefs: Amgen and Wockhardt

Share this article:

Rebounding from its failed Onyx courtship, Amgen announced Tuesday that it has paired up with Servier in a deal that will give it some heft in the cardiovascular space. The collaboration, which garners a $50-million signing fee for Servier, gives Amgen commercial rights to the oral chronic heart failure drug ivabradine, which is approved in the EU under the brand name Procoralan, as well as the exclusive option to develop Servier's S38844, a Phase II heart failure drug. In exchange, Servier scored rights to commercialize Amgen's Phase II heart failure drug omecamtiv in Europe. 

Indian generic drug maker Wockhardt has been locked out of European drug markets. Bloomberg reports that the drug maker's Waluj factory failed to meet UK guidelines. The FDA shut down the company's US distribution from this same plant in May, a move Bloomberg said is forecast to cost the manufacturer around $100 million in sales.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.